Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection.
about
Opportunities for Improved Serodiagnosis of Human Tuberculosis, Bovine Tuberculosis, and ParatuberculosisPrevalence of latent tuberculosis infection in Sudan: a case-control study comparing interferon-γ release assay and tuberculin skin test.Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europePrevalence of latent tuberculosis infection and risk of infection in patients with chronic kidney disease undergoing hemodialysis in a referral center in Brazil.The N-terminal domain of Mycobacterium tuberculosis PPE17 (Rv1168c) protein plays a dominant role in inducing antibody responses in active TB patientsSystematic expression profiling analysis identifies specific microRNA-gene interactions that may differentiate between active and latent tuberculosis infection.Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic.Latent tuberculosis infection: myths, models, and molecular mechanismsFactors associated with the performance of a blood-based interferon-γ release assay in diagnosing tuberculosis.Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB gold in-tube assay.Determining Mycobacterium tuberculosis infection among BCG-immunised Ugandan children by T-SPOT.TB and tuberculin skin testing.Gamma Interferon Assays Used in the Diagnosis of Tuberculosis.High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps.Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection.Interferon-γ release assays for the evaluation of tuberculosis infection.Cough Aerosol Cultures of Mycobacterium tuberculosis: Insights on TST / IGRA Discordance and Transmission DynamicsGene expression profiling identifies candidate biomarkers for active and latent tuberculosisSerological diagnosis of pulmonary Mycobacterium tuberculosis infection by LIPS using a multiple antigen mixture.Close contact interferon-gamma response to the new PstS1(285-374):CPF10: a preliminary 1-year follow-up study.In vitro immunomodulation of a whole blood IFN-γ release assay enhances T cell responses in subjects with latent tuberculosis infection.Effects of acute critical illnesses on the performance of interferon-gamma release assayModulation of mycobacterial-specific Th1 and Th17 cells in latent tuberculosis by coincident hookworm infection.The prevalence of latent Mycobacterium tuberculosis infection based on an interferon-γ release assay: a cross-sectional survey among urban adults in Mwanza, Tanzania.Proteomic analysis of purified protein derivative of Mycobacterium tuberculosisImpact of socioeconomic status and living condition on latent tuberculosis diagnosis among the tribal population of Melghat: A cohort study.The immune response to tuberculosis infection in the setting of Helicobacter pylori and helminth infectionsPredictors of low prevalence of latent tuberculosis infection among Egyptian health care workers at intensive care and bronchoscopy units.Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks.Clinical-Pathological Conference Series from the Medical University of Graz : Case No 162: A 30-year-old woman from Nigeria with fever 3 months postpartum.Evaluation of gamma interferon immune response elicited by the newly constructed PstS-1(285-374):CFP10 fusion protein to detect Mycobacterium tuberculosis infection.Clinical and radiological outcomes after conservative treatment of TB spondylitis: is the 15 years' follow-up in the MRC study long enough?Differential expression of serum/plasma proteins in various infectious diseases: specific or nonspecific signatures.Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention.IFN-γ release assay conversions and reversions. Challenges with serial testing in U.S. health care workers.Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting.Transplanted lungs and the "white plague": A case-report and review of the literature.Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.Occupational Risk of Latent Tuberculosis Infection in Health Workers of 14 Military Hospitals.Tuberculosis screening of new hospital employees: compliance, clearance to work time, and cost using tuberculin skin test and interferon-gamma release assays.
P2860
Q27495985-790AFD35-724C-4DAB-981A-D601C32282A2Q33643951-94B9B6BF-83E5-4342-BDA5-BCC95B0D03A6Q33748685-771F3848-6891-4504-85B1-F8D19CB6036CQ33823947-BE116D57-075D-480B-A5D3-218803B91D04Q33834816-BD05F25C-FEDF-4006-BC9F-AB40F89EB7D3Q34207222-25B1B0A0-C513-4115-BCD1-586AAA64C55BQ34269125-38F307BA-7B70-4610-B3A3-039C2BEAC60FQ34297816-76C327AE-1699-4874-B99C-C8C56528669DQ34305521-90F05009-CA6D-4F86-AF92-72F8C9CE7881Q34365728-E0AE29FF-E1A6-41DC-B622-F48A273907FBQ34450737-83803A3E-DCA6-4FBA-BB48-8B5DB9AAA84AQ34478200-F954CF11-5796-4454-B596-5287834404C7Q34802064-39CC4797-270B-49DC-A717-0FF5980DF604Q35139729-02CD1115-A1E2-4A22-B5B1-12DC34C19BD3Q35220251-D247D2A0-3046-4566-92E9-07B44197EE42Q35783572-7A467E8C-1380-43D4-8C1A-C72F3B2BBE53Q35906290-716A4EEC-DB95-4755-BA97-B90CFBDC6786Q36142835-2623B8EB-6B97-4058-8319-B5D4D3A1858DQ36258046-907A1F8D-BE16-4494-B3BF-15FC195E3BD6Q36353973-80991ACF-1AD1-4F8A-BFF0-4CFC6F26DF49Q36501008-1D32A456-4583-4D38-A3A2-8CBBCD3319A1Q36823951-21C7EAD6-EB4E-416A-9469-E52E01E1D9A0Q36863615-065B354F-E6BD-497D-B2B0-76FAA19C5EF2Q37059722-2D3E316C-A32F-421A-B24D-F22334691D50Q37102132-BB0113B3-0CB7-40A1-83A3-9E9B899D4AAFQ37203318-64ABDBC3-3B1C-432C-9197-2A1EC8C3DA3CQ37335439-3B29365F-2CCF-443E-8120-1D958CB8DF48Q37544916-FD71AB00-4DBB-4D98-8895-A31D259DAEBFQ37584275-C1B397E4-BE1A-4197-A304-199EB022E7DDQ37653930-ABB16292-3477-4413-AC56-1D81FFB84283Q37712824-51850B8F-C797-4307-AD37-A77AFD92CC7AQ38008219-50202F0A-2BE0-48B7-A075-678624AFA989Q38167708-A9D3ED28-712F-41E8-BBA1-22187EC19B49Q38175162-106DBE75-2565-4E2A-A7CF-8B92412800C8Q38180469-86A14EA9-73A6-44AB-BBAA-009EDCF4C490Q38404818-653F2204-D814-496E-BDDC-45843CCD2292Q39206615-5EF8900E-771D-46C3-A606-3E3BF9044B55Q39438318-1C901589-AC72-4489-8D04-A9F1487622EDQ40152484-9A609C5F-A15A-499F-822A-5AF148729D4EQ40221251-796199F1-B210-4789-9803-D671B383A15E
P2860
Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical application and limit ...... latent tuberculosis infection.
@en
Clinical application and limit ...... latent tuberculosis infection.
@nl
type
label
Clinical application and limit ...... latent tuberculosis infection.
@en
Clinical application and limit ...... latent tuberculosis infection.
@nl
prefLabel
Clinical application and limit ...... latent tuberculosis infection.
@en
Clinical application and limit ...... latent tuberculosis infection.
@nl
P2093
P2860
P356
P1476
Clinical application and limit ...... latent tuberculosis infection.
@en
P2093
Julie Parsonnet
Niaz Banaei
Sharon Perry
Victor Herrera
P2860
P304
P356
10.1093/CID/CIR068
P407
P577
2011-04-01T00:00:00Z